A closely cropped shot of two women with their arms intertwined


私達は、バイオ医薬品のリーディングカンパニーと提携して、アンメットメディカルニーズに対処できる科学的相乗効果の領域を特定する機会を常に探し求めています。パートナーシップや協業を通じ、Calla Lily Clinical Careのデバイスを最大限に活用してさらに多様な薬剤、ホルモン、治療薬を標的化および送達し、より幅広い患者さんに利益をもたらすことができます。

Innovate UK logo

Calla Lily Clinical Careおよびその親会社は、英国政府のイノベーション関連機関であるInnovate UKから多大な支援を受けています。2021年11月、当社はInnovate UKから、研究開発の発展を目的とした追加の助成金を承認されました。

University Hospitals Coventry & Warwickshire

CLCC has designed an in-woman trial of our device with progesterone, working closely with the Clinical Trials Unit from University Hospitals Coventry & Warwickshire (UHCW). This is led by Professor Siobhan Quenby, our clinical co-lead and one of the world’s foremost authorities on miscarriage and preterm birth prevention. Siobhan led the highly-cited Lancet series (2021) on miscarriage and was co-applicant, major recruiter to and co-author on the two largest and most significant trials of vaginal progesterone to prevent miscarriage (PROMISE and PRISM). The results of these trials led to the UK’s NICE updating its miscarriage guideline, to now recommend women at high risk of miscarriage to take vaginal progesterone twice daily for up to 80 days – guidance that has subsequently been adopted in Australia and we believe is being closely followed in other countries, with potential to further expand the market opportunity for this indication

パートナーシップやその他の事業開発機会については、Eメール(info@callali.ly)またはお電話(+44 (0) 20 7754 5400)でお問い合わせください。